(Q38399930)

2 September 2017

title

Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer (English)

1 reference

2 September 2017

1 reference

Anna Nordin

1

1 reference

2 September 2017

Wanzhong Wang

series ordinal

2

1 reference

2 September 2017

Karin Welén

series ordinal

3

1 reference

2 September 2017

Jan-Erik Damber

series ordinal

4

1 reference

2 September 2017

publication date

5 November 2012

1 reference

2 September 2017

1 reference

2 September 2017

volume

73

1 reference

2 September 2017

issue

6

1 reference

2 September 2017

page(s)

657-667

1 reference

Estimates of cancer incidence and mortality in Europe in 2008.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Mechanisms of androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Androgen receptor outwits prostate cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Neuroendocrine cells in tumour growth of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine and pleiotrophin in neural development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Promotion of self-renewal of embryonic stem cells by midkine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine is a NF-kappaB-inducible gene that supports prostate cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine induces the transformation of NIH3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine positively regulates the proliferation of human gastric cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Neuroendocrine differentiation in the progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Potential clinical value of circulating chromogranin A in patients with prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Serum chromogranin-A in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Class III β‐tubulin in human development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Increased expression of class III beta-tubulin in castration-resistant human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22607

21 January 2018

Identifiers

DOI

10.1002/PROS.22607

1 reference

2 September 2017

1 reference